Drug Profile
Research programme: heart failure therapeutics - California Institute for Biomedical Research/Pfizer
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator California Institute for Biomedical Research
- Class Antibodies; Heart failure therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure